Skip to content
CPHK
Toggle menu
  • Home
  • This is Us
    • History
    • Goals
    • Core Team
    • Leadership
    • Collaborative Hubs
  • Our Universe
    • Public Health Interests
    • Footprint
    • Research Collaborators
    • Areas of Work
    • Focus
  • Describing Us
    • Proficiencies
    • Approach
    • Projects Undertaken
      • India
      • Tanzania
    • Innovation & Impact
    • Supporting WHO
  • Universal Family
    • Partnerships
    • Funders & Donors
  • Resource Center
    • Publications
    • Workshops
    • Presentations
    • Top Citation
    • Gallery
    • Advertised Positions
  • Global Health
    • Lancet
    • Sci
    • NEJM
    • Tanzania
    • India
    • Global health update
  • Contact

Category: Uncategorized

February 21, 2022Uncategorized

Power and bullying in research

Eric Lander, director of the Office of Science and Technology Policy and science adviser to US President Joe Biden, resigned on Feb […]

February 21, 2022Uncategorized

Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

Worldwide, patients with HoFH are diagnosed too late, undertreated, and at high premature ASCVD risk. Greater use of multi-LLT regimens is associated […]

February 21, 2022Uncategorized

Considerations in boosting COVID-19 vaccine immune responses

A new wave of COVID-19 cases caused by the highly transmissible delta variant is exacerbating the worldwide public health crisis, and has […]

February 21, 2022Uncategorized

COVID-19 will continue but the end of the pandemic is near

The world is experiencing a huge wave of infection with the omicron variant of SARS-CoV-2. Estimates based on Institute for Health Metrics […]

February 21, 2022Uncategorized

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained […]

February 21, 2022Uncategorized

Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden

We found progressively waning vaccine effectiveness against SARS-CoV-2 infection of any severity across all subgroups, but the rate of waning differed according […]

February 21, 2022Uncategorized

Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018

These findings show that intimate partner violence against women was already highly prevalent across the globe before the COVID-19 pandemic. Governments are […]

February 21, 2022Uncategorized

Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021

Efforts to improve pandemic preparedness and response for the next pandemic might benefit from greater investment in risk communication and community engagement […]

February 21, 2022Uncategorized

Medical aid returns to Tigray

Shipments of medical supplies have been delivered to Tigray—the first in months—but WHO says it will not be enough to restock the […]

February 21, 2022Uncategorized

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. […]

Posts pagination

< 1 2 3 4 … 6 >

Recent Posts

  • [Action required] Your RSS.app Trial has Expired.
  • Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis
  • Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
  • Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis
  • The global COVID-19 treatment divide

Recent Comments

    Archives

    • March 2022
    • February 2022
    • October 2019

    Categories

    • Uncategorized
    • work

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Recent News

    • [Action required] Your RSS.app Trial has Expired. March 13, 2022
    • Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis February 26, 2022
    • Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial February 26, 2022

    Categories

    • Uncategorized
    • work

    Archives

    • March 2022
    • February 2022
    • October 2019

    Popular Tags

    CREATIVE IDEAS MUSIC PHOTOGRAPHY UNIQUE WORDPRESS TEMPLATE
    • Home
    • This is Us
    • Our Universe
    • Describing Us
    • Universal Family
    • Resource Center
    • Global Health
    • Contact
    © 2025 CPHK. Proudly powered by Sydney